CN103675300B - Rbx1作为血清标志物的应用及其试剂盒 - Google Patents
Rbx1作为血清标志物的应用及其试剂盒 Download PDFInfo
- Publication number
- CN103675300B CN103675300B CN201410003092.9A CN201410003092A CN103675300B CN 103675300 B CN103675300 B CN 103675300B CN 201410003092 A CN201410003092 A CN 201410003092A CN 103675300 B CN103675300 B CN 103675300B
- Authority
- CN
- China
- Prior art keywords
- rbx1
- cancer
- kit
- serum
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 title claims abstract description 181
- 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 title claims abstract description 176
- 101710178916 RING-box protein 1 Proteins 0.000 title claims abstract description 176
- 210000002966 serum Anatomy 0.000 title claims abstract description 97
- 238000012546 transfer Methods 0.000 claims abstract description 48
- 238000011156 evaluation Methods 0.000 claims abstract description 37
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 27
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 27
- 201000002313 intestinal cancer Diseases 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 24
- 201000007270 liver cancer Diseases 0.000 claims abstract description 24
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 24
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 23
- 238000012544 monitoring process Methods 0.000 claims abstract description 21
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 20
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 20
- 238000003745 diagnosis Methods 0.000 claims abstract description 16
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims abstract description 15
- 201000000498 stomach carcinoma Diseases 0.000 claims abstract description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 238000002965 ELISA Methods 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 101001111715 Mus musculus E3 ubiquitin-protein ligase RBX1 Proteins 0.000 claims description 4
- 239000003593 chromogenic compound Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 73
- 238000011282 treatment Methods 0.000 abstract description 62
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000013399 early diagnosis Methods 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 description 22
- 238000002512 chemotherapy Methods 0.000 description 13
- 206010017758 gastric cancer Diseases 0.000 description 13
- 201000011549 stomach cancer Diseases 0.000 description 13
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000012749 thinning agent Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 101001111722 Homo sapiens E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 5
- 229960000074 biopharmaceutical Drugs 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 101100140195 Caenorhabditis elegans rbx-1 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
患者编号 | 治疗前后浓度比值 | 临床评价 |
01 | 1.252 | 无效 |
02 | 0.287 | 疗效显著 |
03 | 0.577 | 无效 |
04 | 0.637 | 改善 |
05 | 1.341 | 无效 |
06 | 1.668 | 无效 |
07 | 1.277 | 无效 |
08 | 0.506 | 疗效显著 |
09 | 0.711 | 改善 |
10 | 1.462 | 无效 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
01 | 0.774 | 0.869 | 1.120 | 1.328 | 转移复发 |
02 | 1.148 | 1.219 | 1.235 | 1.369 | 无进展生存 |
03 | 1.083 | 1.085 | 1.113 | 1.416 | 无进展生存 |
04 | 1.012 | 1.242 | 1.244 | 1.290 | 无进展生存 |
05 | 0.884 | 1.001 | 1.152 | 1.232 | 转移复发 |
06 | 1.084 | 1.244 | 1.645 | 1.700 | 无进展生存 |
患者编号 | 治疗前后浓度比值 | 临床评价 |
01 | 1.487 | 无效 |
02 | 0.861 | 改善 |
03 | 1.278 | 无效 |
04 | 0.476 | 疗效显著 |
05 | 1.463 | 无效 |
06 | 1.723 | 无效 |
07 | 0.710 | 改善 |
08 | 1.018 | 改善 |
09 | 1.264 | 无效 |
10 | 1.548 | 无效 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
01 | 1.147 | 1.171 | 1.172 | 1.218 | 无进展生存 |
02 | 0.582 | 0.993 | 1.09 | 1.222 | 转移复发 |
03 | 0.833 | 0.977 | 1.008 | 1.163 | 转移复发 |
04 | 1.184 | 1.368 | 1.397 | 1.52 | 无进展生存 |
05 | 0.933 | 0.954 | 1.085 | 1.332 | 转移复发 |
06 | 1.032 | 1.125 | 1.379 | 1.402 | 无进展生存 |
患者编号 | 治疗前后浓度比值 | 临床评价 |
01 | 1.732 | 无效 |
02 | 0.689 | 改善 |
03 | 0.515 | 改善 |
04 | 1.281 | 无效 |
05 | 0.744 | 改善 |
06 | 1.297 | 无效 |
07 | 1.346 | 无效 |
08 | 1.628 | 无效 |
09 | 0.306 | 疗效显著 |
10 | 1.711 | 无效 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
01 | 0.501 | 0.841 | 1.183 | 1.392 | 转移复发 |
02 | 1.118 | 1.056 | 1.034 | 1.139 | 无进展生存 |
03 | 1.300 | 1.193 | 1.281 | 1.043 | 无进展生存 |
04 | 1.155 | 1.191 | 1.254 | 1.202 | 无进展生存 |
05 | 1.096 | 1.178 | 0.974 | 1.098 | 无进展生存 |
06 | 0.564 | 0.781 | 0.933 | 1.249 | 转移复发 |
患者编号 | 治疗前后浓度比值 | 临床评价 |
01 | 1.295 | 无效 |
02 | 1.646 | 无效 |
03 | 0.503 | 疗效显著 |
04 | 1.322 | 无效 |
05 | 1.441 | 无效 |
06 | 0.573 | 无效 |
07 | 0.748 | 改善 |
08 | 0.836 | 改善 |
09 | 1.116 | 无效 |
10 | 0.709 | 改善 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
01 | 0.896 | 1.007 | 1.136 | 1.238 | 转移复发 |
02 | 0.869 | 0.94 | 0.992 | 1.306 | 转移复发 |
03 | 1.145 | 1.261 | 1.402 | 1.575 | 无进展生存 |
04 | 1.183 | 1.295 | 1.415 | 1.443 | 无进展生存 |
05 | 0.772 | 0.925 | 1.023 | 1.263 | 转移复发 |
06 | 0.882 | 1.289 | 1.399 | 1.424 | 转移复发 |
患者编号 | 治疗前后浓度比值 | 临床评价 |
01 | 0.798 | 改善 |
02 | 1.689 | 无效 |
03 | 0.643 | 改善 |
04 | 1.427 | 无效 |
05 | 0.889 | 改善 |
06 | 1.207 | 无效 |
07 | 1.183 | 改善 |
08 | 1.189 | 无效 |
09 | 0.437 | 无效 |
10 | 0.330 | 有效 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
01 | 0.905 | 0.960 | 0.984 | 1.257 | 转移复发 |
02 | 1.007 | 1.160 | 1.432 | 1.569 | 转移复发 |
03 | 1.079 | 1.086 | 1.087 | 1.114 | 无进展生存 |
04 | 1.207 | 1.367 | 1.638 | 1.663 | 无进展生存 |
05 | 0.869 | 0.971 | 0.973 | 1.269 | 转移复发 |
06 | 1.310 | 1.334 | 1.439 | 1.482 | 无进展生存 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410003092.9A CN103675300B (zh) | 2014-01-03 | 2014-01-03 | Rbx1作为血清标志物的应用及其试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410003092.9A CN103675300B (zh) | 2014-01-03 | 2014-01-03 | Rbx1作为血清标志物的应用及其试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103675300A CN103675300A (zh) | 2014-03-26 |
CN103675300B true CN103675300B (zh) | 2015-10-14 |
Family
ID=50313486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410003092.9A Active CN103675300B (zh) | 2014-01-03 | 2014-01-03 | Rbx1作为血清标志物的应用及其试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103675300B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112480231B (zh) * | 2020-12-14 | 2022-05-24 | 上海交通大学 | 一种生物活性肽kqslppglavkdlk及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2604703A2 (en) * | 2005-03-14 | 2013-06-19 | The Board of Trustees of Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
-
2014
- 2014-01-03 CN CN201410003092.9A patent/CN103675300B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2604703A2 (en) * | 2005-03-14 | 2013-06-19 | The Board of Trustees of Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
Non-Patent Citations (1)
Title |
---|
Small RING Finger Proteins RBX1 and RBX2 of SCF E3 Ubiquitin Ligases: The Role in Cancer and as Cancer Targets;Dongping Wei;《Genes & Cancer》;20100731;第1卷(第7期);第700-707页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103675300A (zh) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103898205B (zh) | 半胱氨酸蛋白酶抑制剂sn的应用 | |
CN102317784B (zh) | 作为癌症标记物的armet | |
CN101449163B (zh) | S100a12蛋白作为结肠直肠癌标记的用途 | |
CN103940996B (zh) | Cystatin SN和AFP在制备诊断和预示肝癌标志物中的应用 | |
Zhou et al. | Postoperative Serum Osteopontin Level is a Novel Monitor for Treatment Response and Tumor Recurrence after Resection of Hepatitis B–related Hepatocellular Carcinoma | |
US20180216194A1 (en) | Compositions and methods for detecting pancreatic cancer | |
CN103675300B (zh) | Rbx1作为血清标志物的应用及其试剂盒 | |
CN103901205B (zh) | Cystatin SN与CYFRA21-1在制备诊断和预示食管癌标志物中的应用 | |
CN102138074B (zh) | 用作肺癌标记物的asc | |
Wang et al. | Prognostic values of B7-H4 in non-small cell lung cancer | |
CN103913576B (zh) | Cystatin SN 和CA15-3在制备诊断和预示乳腺癌标志物中的应用 | |
CN103901207B (zh) | Cystatin S和CA15-3在制备诊断和预示乳腺癌标志物中的应用 | |
EP2743701B1 (en) | Method of diagnosing surgical site infections | |
CN104062436B (zh) | Fxyd在制备诊断和预示肺癌标志物中的应用及fxyd双抗夹心elisa检测试剂盒 | |
JP5571171B2 (ja) | 肺癌のマーカーとしてのcybp | |
CN103966351A (zh) | CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 | |
CN103941016B (zh) | 半胱氨酸蛋白酶抑制剂sn与癌胚抗原的联合应用 | |
CN103901196B (zh) | Cystatin S和CYFRA21-1在制备诊断和预示食管癌标志物中的应用 | |
CN103926409B (zh) | Cystatin S和AFP在制备诊断和预示肝癌标志物中的应用 | |
US20150377889A1 (en) | Galectin-3 as a marker for prostate cancer | |
CN108287239A (zh) | 血清ca2蛋白在制备肝癌诊断或预后评估试剂盒中的应用 | |
Taraskin et al. | A novel method for multiplex protein biomarker analysis of human serum using quantitative MALDI mass spectrometry | |
CN103913575A (zh) | 半胱氨酸蛋白酶抑制剂s与糖类抗原19-9的联合应用 | |
CN103911426B (zh) | 半胱氨酸蛋白酶抑制剂s的应用 | |
Li et al. | Combination of serum matrix metalloproteinase-3 activity and EBV antibodies improves the diagnostic performance of nasopharyngeal carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 BioBAY No. 218 building, Room 301, C4 201 Patentee after: Jiangsu is the real biopharmaceutical technology Limited by Share Ltd Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 No. 218 BioBAY C4-201 Patentee before: Suzhou Micro Diag Biomedicine Co., Ltd. |
|
CP03 | Change of name, title or address | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140326 Assignee: Suzhou ronghua Leasing Co., Ltd Assignor: JIANGSU MICRODIAG BIOMEDICAL TECHNOLOGY Co.,Ltd. Contract record no.: X2020320010029 Denomination of invention: Application of rbx1 as serum marker and its kit Granted publication date: 20151014 License type: Exclusive License Record date: 20201204 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of rbx1 as serum marker and its kit Effective date of registration: 20201207 Granted publication date: 20151014 Pledgee: Suzhou ronghua Leasing Co., Ltd Pledgor: JIANGSU MICRODIAG BIOMEDICAL TECHNOLOGY Co.,Ltd. Registration number: Y2020320010220 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Suzhou ronghua Leasing Co., Ltd Assignor: JIANGSU MICRODIAG BIOMEDICINE TECHNOLOGY Co.,Ltd. Contract record no.: X2020320010029 Date of cancellation: 20211217 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211221 Granted publication date: 20151014 Pledgee: Suzhou ronghua Leasing Co., Ltd Pledgor: JIANGSU MICRODIAG BIOMEDICINE TECHNOLOGY Co.,Ltd. Registration number: Y2020320010220 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |